Post on 26-Sep-2020
Assessing the impact of formulation on protein-based biotherapeutics
Bradley, Derek1; Stocca, Alessia2; Burke, Mary1; Roche, James J.2
1 BioClin Research Laboratories, IDA Technology Park, Garrycastle, Athlone, Co. Westmeath, Ireland 2 Biosciences Research Institute, Athlone Institute of Technology, Dublin Road, Athlone, Co Westmeath, Ireland.
Abstract
Biopharmaceuticals are a class of revolutionary drugs that have been developed to treat a diverse range of serious
and often life-threatening diseases, such as cancer. As with small molecule drugs, they must be tested to ensure they
meet predefined specifications prior to release. However, owing to their complexity, the analytical challenges for
biopharmaceuticals are far greater than for small molecule drugs. Being protein in nature, biopharmaceutical
structure can be dramatically altered by formulation excipients. This may lead to an inefficacious drug, or indeed,
one which may have a significantly altered safety profile.
In this research, the following range of analytical techniques have been applied to two assumed-identical
asparaginase formulations, a biopharmaceutical that is used to treat acute lymphoblastic leukaemia (ALL) in children:
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Intact mass (‘top-down’) analysis – mass spectrometry
Peptide mass fingerprinting (primary structure analysis)
Amino acid compositional analysis
Spectroscopic analysis – circular dichroism (CD)
Results show that the formulations exhibit highly similar responses in some analytical techniques, but not others.
This demonstrates that in order to characterise the impact of formulation on biological medicines, an orthogonal
analytical approach, comprising a battery of techniques which offer complimentary information, should be
employed.
Introduction
Biopharmaceuticals are protein-based therapeutics, which only function as intended when they adopt the correct
structure and three-dimensional shape. Proteins have several layers of assembly, each of which play a critical role in
determining overall protein shape. Alterations at any level of structure may result in an incorrectly folded protein,
which could give rise to a molecule with reduced efficacy, or potentially trigger a harmful immune response.(1-2)
Formulation of a biopharmaceutical product can dramatically influence the stability and structure of the protein, due
to interactions between the amino acid variable groups and formulation excipients or processes.(3) For example,
development of modified forms (such as aggregates) may be promoted during lyophilisation,(4) while certain
excipients may contribute to chemical modifications, such as oxidation.(5) Therefore, a key aspect of product
development is that the influence of formulation on stability and structure of biologics should be thoroughly
characterised.
This research is a joint industry/academia collaborative effort which aims to explore and develop methods to
characterise biopharmaceuticals. Development of robust techniques capable of reliably detecting differences in
biopharmaceutical structure is critical to ensuring patient safety. The rapid emergence of biosimilars (copy-versions
of innovator biologics authorised under abbreviated licensure pathways) underlines the increasing need for
availability of such techniques.
Methods and Materials
Samples for all tests were lyophilisates which were reconstituted in water according to manufacturer’s instructions –
final concentration was approximately 13.0 mg/mL. Reconstituted material was stored frozen at -80ºC in single-use
aliquots. When required, aliquots were thawed at room temperature. The following sections briefly describe the
methods for each test (experimental settings were optimised for each test during pilot-scale experiments) – further
details can be obtained by contacting the author.
SDS-PAGE: Samples were diluted with water to 1.0, 0.5 and 0.2 mg/mL. 100 µL of each dilution was combined with
an equal volume of 2X Laemmli sample buffer containing 100 mM DTT – this gives final protein concentrations of
0.5, 0.25 and 0.1 mg/mL, respectively. 20 µL of each preparation was pipetted into the wells of an ‘Any-kD, Stain-
free’ polyacrylamide gel (BioRad, product code # 456-8123), according to Figure 1 – this volume corresponds to a
total protein load of 10, 5 and 2 µg, respectively. Samples were electrophoresed at 200 V (constant voltage) using
the Mini-Protean electrophoresis system from BioRad – run time was 30 minutes. The gel was then imaged using the
‘Stain-free’-enabled ChemiDoc MP Imaging system from BioRad. Data was processed using ImageLab Software
version 5.4.1., Security Edition.
Intact mass analysis: Samples were diluted in 50% (v/v) acetonitrile containing 0.1% (v/v) formic acid to a final
concentration of 50 µg/mL. Samples were then infused using a Harvard 22 apparatus and syringe with a flow rate of
20 µL/min into the electrospray ionisation source of the API3000 mass spectrometer (ABSciex). The mass
spectrometer ionisation and detection settings were as detailed in Table 1, below. Data was analysed using Analyst
version 1.4 software.
Table 1: Instrument settings for intact mass analysis via MS
Peptide mass fingerprinting: Samples were diluted to 1.0 mg/mL with water. 50 µL of each sample (corresponding
to 50 µg of protein) was desalted using a solid phase extraction cartridge containing C8 resin. Samples were
evaporated to dryness in a vacuum centrifuge, then resuspended in 20 µL of 50 mM ammonium bicarbonate
containing 8 M urea. 5 µL of 45 mM dithiothreitol (DTT) was added followed by incubation at 60ºC for 45 minutes,
during which disulfide bonds were reduced. Then, 10 µL of iodoacetamide (IAA) was added, and tubes incubated at
room temperature in the dark for 45 minutes, during which free cysteines were alkylated to prevent disulfide bonds
reforming. A further 5 µL of 45 mM DTT was then added to neutralise excess IAA. Final volume was brought to 200
µL with water in order to dilute urea to below 1.0 M, as high urea concentration is not compatible with trypsin. 2 µL
of 1.0 mg/mL sequencing-grade trypsin was then added, and tubes incubated at 37ºC for 24 hours. Following
incubation, digestion was stopped by freezing the samples at -20ºC until required for analysis. Samples were diluted
1:1 with mobile phase A (see below) and 40 µL injected. Analysis was on the API3000 LC-MS/MS (ABSciex) system
with Perkin Elmer 200 Series autosampler and quaternary pump. Mass spectrometer settings were as detailed in
Table 1, with the exception that source temperature was 400ºC. The column was a C18-AR type, with dimensions of
4.0 mm (I.D.) X 150 mm (length) with 3 µm particle size. Samples were eluted with a 120 minute linear gradient from
2% (v/v) acetonitrile with 0.1% (v/v) formic (Mobile phase A) acid to 50% (v/v) acetonitrile with 0.1% (v/v) formic
acid (Mobile phase B). Flow rate was 1.0 mL/min, which was split with approximately 0.5 mL/min going to the source
(the remainder going to waste). Data was collected and analysed using Analyst version 1.4 software.
Amino acid compositional analysis: Samples were prepared at a concentration of 1.0 mg/mL. 2 µL of each sample (2
µg of protein) was added to an autosampler vial and evaporated to dryness. 200 µL of 6 N HCl containing 0.1% (w/v)
phenol was added, then the headspace of tubes purged with a stream of nitrogen before being capped tightly. Tubes
were then placed in a vacuum oven at 115ºC for 24 hours, during which peptide bonds are hydrolysed, releasing the
free amino acids. Following hydrolysis, HCl was evaporated off, then amino acids derivatised using the Waters AccQ-
Tag chemistry package. Analysis was on the Varian ProStar Fluorescence HPLC System. The column was a Nova-Pak
C18, (4.0 mm I.D., 150 mm in length, 4 µm particle size). A linear gradient from 2% to 50% B over 60 minutes, with a
flow rate of 1.0 mL/min was used for analysis. Injection volume was 5 µL. Standards from 0 to 100 µM of each amino
acid were also prepared from commercially available amino acid standards. These were also derivatised and
analysed in order to quantify the amount of each respective amino acid present in the test samples. Data collection
and processing was performed using Varian Star Chromatography Workstation software.
Circular dichroism: CD analysis was performed at Applied Photophysics, Leatherhead, UK. Samples were diluted
approximately 1:20 with water to reduce absorbance to about 1.8 A.U., which is required for CD analysis. A
lyophilised vial of asparaginase was also analysed – this was also diluted with water in order to obtain an absorbance
of approximately 1.8 A.U. Samples were scanned on the Chirascan Plus qCD Spectrometer. Analysis was performed
in isothermal mode (at 20ºC) in the far UV region (260 to 180 nm), with a wavelength increment of 1 nm, and a
bandwidth of 1 nm. Samples were also analysed with temperature ramping in order to compare melting
temperatures. For temperature ramping experiments, the scan range was from 250 to 190 nm, wavelength
increment of 1 nm, bandwidth of 1 nm, and temperature ramped from 20ºC to 90ºC in 1ºC increments. Applied
Photophysics’ Global 3 software was used for data analysis.
Results
Results from sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Figure 1: Left – gel imaged following electrophoresis with bands for standards and samples auto-detected in ImageLab
software v. 5.4.1. Right – green filter applied to image revealing the presence of additional high molecular weight protein bands (red arrows)
Table 2: Molecular masses estimated from SDS-PAGE
Results from intact mass analysis via mass spectrometry
Figure 2: Centroided spectra from electrospray ionisation mass spectrometry of asparaginase samples: Left – M030614; Right – R030614.
Figure 3: Characteristic electrospray ionisation charge envelope for M030614 in profile; right – calculation of intact molecular mass from charge envelope data.
Results from peptide mass fingerprinting via ESI LC-MS
Figure 4: Peptide mass fingerprints: Top – recombinant asparaginase; Bottom – non-recombinant asparaginase.
In each figure, the top panel represents the total ion current (TIC) for peptides. The three lower panels are extracted ion chromatograms
for three selected peaks, which gives the molecular mass of the peptide fragments, which allows their identity to be confirmed
Results from amino acid compositional analysis
Figure 5: example standard curve for isoleucine showing excellent correlation
Figure 6: Representative chromatogram for 75 µM derivatised amino acid standard preparation
Table 3: Comparison of the amino acid composition of asparaginase samples
Table 4: Correlation of amino acid standard curves from amino acid analysis
Results from circular dichroism analysis
Discussion
Intact mass analysis via mass spectrometry revealed that the active ingredient in both preparations had the same
molecular mass (to within 1 Da of each other, which is below the 10 p.p.m. error typically allowed when reporting
intact mass results for proteins) (Figures 2 and 3). Post-translation modifications such as glycosylation, or sample
degradation processes, such as oxidation or deamidation, would have a major impact on intact molecular mass.
However, this was not observed for these samples, which indicates that the samples had not undergone such
changes. Peptide mapping data provided confirmation that the amino acid sequence of each protein sample was the
same, as digestion with the same proteolytic enzyme (trypsin) under the same experimental conditions yielded
identical fragments (Figure 4).
These data support the assumption that the active ingredient (asparaginase) in both preparations was identical.
However, results from circular dichroism analysis and SDS-PAGE suggest that differences exist between the
formulations. Very significant differences in CD spectra from 200 to 180 nm were observed (Figures 7 to 9). This
could suggest a secondary or tertiary structural change (i.e. how the protein is folded in three-dimensional space),
but could also be explained by the presence of far U.V-absorbing excipients in the recombinant formulation, that are
not present in the non-recombinant version. This could be further explored by repeating the CD analysis, but this
time, removing potential excipients via solid-phase extraction prior to analysis.
Analysis via SDS-PAGE revealed that there were some additional high-molecular mass bands in the non-recombinant
asparaginase (with molecular masses ranging from 50 to 100 kDa, by reference to the molecular mass standards)
(Figure 1). These may potentially be aggregates of asparaginase (dimers of the asparaginase protein unit). The
presence of these aggregates in one formulation but not in the other is potentially due to the differences in
formulation that are evident from CD analysis, as some excipients may prevent (or promote) aggregate formation,
particularly during storage.
Results from amino acid compositional analysis compared quite well between both asparaginase samples, with 14
out of 17 amino acids having relative standard deviations of less than 15%. However, experimental results did not
correlate with the expected composition. This is thought to be due to trace levels of some amino acids, such as
glycine, in the reagent-grade chemicals used. Subsequent work on amino acid analysis will attempt to eliminate
these sources of contamination. Standard curves for each amino acid have correlation coefficients of > 0.99.
Conclusions
The impact of formulation excipients on the structural characteristics of biopharmaceuticals should be thoroughly
evaluated. A battery orthogonal analytical approaches should be employed, as differences (such as propensity to
form aggregates which may impact on product safety or efficacy), may not be readily revealed using techniques such
as ‘top-down’ mass spectrometry alone.
References
1. Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals.
Molecular Biotechnology. 2008 Jun 1;39(2):113-8.
2. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and anti-erythropoietin antibodies in
patients treated with recombinant erythropoietin. The New England Journal of Medicine. 2002;346(7):469-75.
3. Zhang J, Banks DD, He F, Treuheit MJ, Becker GW. Effects of Sucrose and Benzyl Alcohol on GCSF Conformational Dynamics Revealed
by Hydrogen Deuterium Exchange Mass Spectrometry. Journal of Pharmaceutical Sciences. 2015 May 1;104(5):1592-600.
4. Roughton BC, Iyer LK, Bertelsen E, Topp EM, Camarda KV. Protein aggregation and lyophilization: Protein structural descriptors as
predictors of aggregation propensity. Computers & Chemical Engineering. 2013 Nov 11;58:369-77.
5. Lipiäinen T, Peltoniemi M, Sarkhel S, Yrjönen T, Vuorela H, Urtti A, Juppo A. Formulation and Stability of Cytokine Therapeutics.
Journal of Pharmaceutical Sciences. 2015 Feb 1;104(2):307-26.
Contact Information
Mary Burke
Managing Director,
Biopharmaceuticals Department,
BioClin Research Laboratories,
IDA Business & Technology Park
Garrycastle, Athlone,
Co. Westmeath
N37 X061
Email: jroche@ait.ie
Phone: +353 (0) 90 6468087
Fax: +353 (0) 90 646 8148
Derek Bradley (M.Sc.)
Senior Scientist
Biopharmaceuticals Department
BioClin Research Laboratories,
IDA Business & Technology Park
Garrycastle, Athlone,
Co. Westmeath
N37 X061
Email: derek.bradley@bioclinlabs.com
Phone: +353 (0) 90 646 0200
Fax: +353 (0) 90 646 0210
Acknowledgements
We wish to thank Applied Photophysics, Leatherhead, UK for performing
circular dichroism analysis and providing the data included on this poster.